MarketMoodz
Independent Pharmacies Sue Prime Therapeutics Over Price-Fixing
Nearly 5,000 independent pharmacies, through TRUST LLC, filed an antitrust and breach-of-contract suit accusing Prime Therapeutics of conspiring with Cigna’s Express Scripts to depress reimbursements and raise fees. The complaint also spotlights arbitration-game disputes that could delay or limit pharmacies’ ability to win relief.
Key Takeaways
- About 5,000 independent pharmacies, represented by TRUST LLC, allege Prime conspired with Express Scripts to lower reimbursements and increase fees under a 2019 agreement.
- Prime added a mandatory arbitration amendment to pharmacy contracts effective Dec. 1, 2024; TRUST initially filed with JAMS in Oct. 2025 and later with the AAA in April 2026.
- Plaintiffs claim Prime refused to commit to a dispute forum, effectively blocking claims despite mandatory arbitration provisions.
- The suit seeks federal antitrust damages and breach-of-contract relief, alleging both per se restraints and Rule of Reason violations.
- If upheld, the claims could raise antitrust liability for PBMs and reshape reimbursement, fee disclosures, and margins for independent pharmacies.
People Involved
- No specific individuals mentioned
Entities Involved
- Independent pharmacies (~5,000) Plaintiffs represented by TRUST LLC
- TRUST LLC Entity formed by the National Community Pharmacists Association to assign pharmacy claims
- National Community Pharmacists Association (NCPA) Trade group that formed TRUST LLC
- Prime Therapeutics Pharmacy benefits administrator accused of conspiring to suppress reimbursements and increase fees
- Express Scripts PBM allegedly party to a 2019 agreement with Prime Therapeutics
- Cigna Group (CI) Parent company of Express Scripts
- JAMS Arbitration forum named in Prime’s Dec. 1, 2024 contract amendment
- American Arbitration Association (AAA) Forum where TRUST filed arbitration in April 2026
MarketMoodz Analysis
For investors, the suit raises two immediate risks: legal liability for PBM-related businesses and operational pressure on independent pharmacies. If courts find the alleged 2019 agreement unlawfully reduced reimbursements while shifting fees, PBMs could face substantial damages and increased regulatory scrutiny—risks that can compress margins for companies tied to PBM revenues and alter valuation multiples for insurers that own PBM units.
The arbitration battle matters almost as much as the underlying antitrust theory. Prime’s December 2024 JAMS amendment and subsequent forum challenges create a procedural gauntlet that can delay discovery, raise defense costs, and limit collective remedies. Historical antitrust suits against PBMs and health-care intermediaries often settle after protracted litigation; delays favor deep-pocketed defendants and can reduce the size or likelihood of recoveries for dispersed plaintiffs like independent pharmacists.
Watch for three developments that will move markets: court rulings on appropriate arbitration forums, any produced contract or pricing evidence showing confidential data-sharing, and regulator attention from the FTC or state attorneys general. A decisive win for pharmacies could force greater transparency around DIR fees, rebates and reimbursement formulae; a win for Prime/Express Scripts would reinforce PBM leverage and likely sustain current reimbursement dynamics.
Source: Original Article